Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets By: Benzinga via Benzinga January 05, 2017 at 16:10 PM EST The total number of M&A deals dipped a bit in 2016, but total deal value surged 44 percent to $218.9 billion. With interest rates ... Read More >> Related Stocks: Gilead Sciences Incyte Corp Intercept Pharmaceuticals Ionis Pharmaceuticals Tesaro Inc